A look at Intellia Therapeutics, Inc. and Editas Medicine, Inc., including their restructuring and pipeline prioritization. Read more about EDIT and NTLA stocks here.

Equities research analysts at Leerink Partnrs decreased their FY2025 earnings per share (EPS) estimates for Editas Medicine in a note issued to investors on Wednesday, January 22nd. Leerink Partnrs ...

Editas Medicine Inc (EDIT) stock saw a modest uptick, ending the day at $1.41 which represents a slight increase of $0.07 or 5.22% from the prior close of $1.34. The stock opened at $1.37 and touched ...

Editas Medicine Inc (EDIT) stock saw a decline, ending the day at $1.22 which represents a decrease of $-0.02 or -1.61% from the prior close of $1.24. The stock opened at $1.26 and touched a low of $1 ...

Analysts at Zacks Research decreased their FY2024 earnings per share (EPS) estimates for Editas Medicine in a report issued on Tuesday, January 21st. Zacks Research analyst A. Chakraborty now expects ...

Editas Medicine (EDIT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Yanan Zhu from Wells Fargo maintained a Hold rating on the ...

Editas Medicine (EDIT) announced its three-year strategic priorities, anticipated 2025 key milestones, and new in vivo preclinical proof of concept data in non-human primates editing hematopoietic ...

CAMBRIDGE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today ...

CAMBRIDGE, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading gene editing company, today announced that the Company’s President and CEO Gilmore O’Neill ...

CRISPR Therapeutics' stock decline is likely influenced by Editas Medicine's struggles, but CRISPR remains a distinct and stronger company with a promising long-term outlook. CRISPR's strategic ...